Disclosure Of Entity's Operating Segments [Text Block]

Alligator Bioscience - Filing #679585

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Disclosure of entity's operating segments [text block]
För både 2023 och 2022 är koncernens nettoomsättning främst relaterat till förskningsamarbete och
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Depreciation and amortisation expense
10 489 SEK
11 767 SEK
Tax expense (income)
- SEK
- SEK
Profit (loss) before tax
248 586 SEK
193 403 SEK
Profit (loss)
- SEK
- SEK
248 586 SEK
248 586 SEK
- SEK
193 403 SEK
193 403 SEK
- SEK
Assets
118 450 SEK
169 584 SEK
Cash flows from (used in) operating activities
189 286 SEK
172 607 SEK
Cash flows from (used in) investing activities
2 459 SEK
440,000 SEK
Cash flows from (used in) financing activities
161 561 SEK
7 827 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.